Mark Genovese
Expertise in
8
conditions

Dr. Mark Genovese

Rheumatology
Stanford Hospital And Clinics
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
31 Years of Experience
Expertise in
8
conditions
Stanford Hospital And Clinics
300 Pasteur Dr, 
Stanford, CA 

Overview

Mark Genovese is a Rheumatologist practicing medicine in Stanford, California. He has been practicing medicine for over 31 years.

Dr. Genovese is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis.

He is actively involved in clinical research, co-authoring 163 peer reviewed articles and participating in 7 clinical trials.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305
Other Locations
Tanya W Spirtos MD Wommens Cancer
900 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: Sarilumab
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

163 Total Publications

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 03, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Lorinda Chung
Rheumatology
Expertise in
12
conditions
Dr. Lorinda Chung
Rheumatology

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-6961
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lorinda Chung is a Rheumatologist practicing medicine in Stanford, California. Dr. Chung is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Scleroderma, Systemic Sclerosis (SSc), Dermatomyositis, and Polymyositis.

Expertise in
11
conditions
Dr. Vibeke Strand
Rheumatology
Expertise in
11
conditions
Dr. Vibeke Strand
Rheumatology

Office

306 Ramona Rd, 
Portola Valley, CA 
 (6.2 miles away)
650-529-0150
Languages Spoken:
English
See accepted insurances

Vibeke Strand is a Rheumatologist practicing medicine in Portola Valley, California. Dr. Strand is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Tissue Biopsy.

Expertise in
2
conditions
Dr. David Wofsy
Rheumatology
Expertise in
2
conditions
Dr. David Wofsy
Rheumatology

San Francisco VA Medical Center

4150 Clement St, 
San Francisco, CA 
 (30.1 miles away)
415-221-4810
Languages Spoken:
English
See accepted insurances

David Wofsy is a Rheumatologist practicing medicine in San Francisco, California. Dr. Wofsy is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Lupus Nephritis and Systemic Lupus Erythematosus (SLE).

Frequently Asked Questions about Dr. Mark Genovese

How do I make an appointment with Dr. Mark Genovese?

You can book an appointment with Dr. Mark Genovese by calling their office at 650-723-6961. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark Genovese a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark Genovese is classified as an Elite expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark Genovese specialize in?

While Dr. Mark Genovese is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Arthritis, and Psoriatic Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Mark Genovese participate in research or clinical trials?

Yes. Dr. Mark Genovese has published 163 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Mark Genovese's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark Genovese accept my insurance?

Dr. Mark Genovese accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-723-6961 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Genovese's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile